Creating Equitable Access

San Francisco, CA   |
GuideStar Charity Check


EIN: 26-4443340


Medicines360 is a non-profit pharmaceutical organization working toward a world where all women have access to the medicines they need. Our mission is to catalyze equitable access to medicines & devices through product development, policy advocacy, and collaboration with U.S. and global partners.

Ruling year info


Principal Officer

Tina Raine-Bennett, MD, MPH

Main address

49 Stevenson Street Suite 1100

San Francisco, CA 94105 USA

Show more contact info



Subject area info

Philanthropy and public policy

Health care access

Reproductive health care


Diseases and conditions

Population served info

Women and girls

NTEE code info

(Research Institutes and/or Public Policy Analysis) (G05)

IRS subsection

501(c)(3) Public Charity

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Tax forms



Programs and results

What we aim to solve

SOURCE: Self-reported by organization

We believe the nonprofit pharma model can help speed the transformation of the healthcare system to ensure equitable access to life-altering medicines. Unbeholden to shareholder interests, our model is catalyzing increased access to affordable medicines that address unmet medical needs for women’s health.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Conducting pharmaceutical development to bring new medicines to market

Founded in 2009 because the most effective forms of reversible contraception were too expensive and out of reach, Medicines360 is a nonprofit pharmaceutical organization that prioritizes women over profit to ensure equitable access to medicines.

Today, our focus is to develop and provide a broader range of high-quality products that will help fill gaps in women’s health. Our experience in drug development, clinical trial research, and regulatory affairs makes us uniquely positioned to address the high cost of medicines in the U.S and globally.

Medicines360 has products called LILETTA® and AVIBELA™ that are available in many countries and regions, but not all.

Population(s) Served

Continually assess the market to identify barriers women face in accessing the health products they need.

Population(s) Served

Forming key relationships with nonprofits, pharmaceutical companies, and global non-governmental organizations (NGOs) who are critical to helping develop, distribute, and market medicines in the US and globally.

Population(s) Served
Women and girls
Women and girls
Women and girls

Where we work

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Number of products distributed

This metric is no longer tracked.
Totals By Year
Related Program

Conducting pharmaceutical development to bring new medicines to market

Type of Metric

Output - describing our activities and reach

Direction of Success

Holding steady

Context Notes

To date, in collaboration with our commercial partner, we have made our hormonal IUD available to more than 1.2 million women throughout the United States.

Our Sustainable Development Goals

SOURCE: Self-reported by organization

Learn more about Sustainable Development Goals.

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

Since our founding in 2009, we have learned critical lessons that have informed our priorities for the next chapter in our pursuit of equitable access. Complex problems require multi-faceted, long-term solutions. As a social enterprise, we are driven to help make equitable access to medicines a reality for women. Our organization has developed momentum to address one of the most pressing issues that plague our current system – the high cost of drugs that prohibits access for many women. We will continue engaging with stakeholders and philanthropic donors to bring new and expanded resources to our work in product development, policy advocacy, and public sector engagement.

Key Priorities:

1. Grow Our Impact: Expand the portfolio of women's health products that increase access and/or healthcare choice

2. Deliver on Medicines360's Promise: Expand AVIBELA's global impact

3. Capitalize on Our Success: Maximize our impact and act as a catalyst for change

4. Create Points of Leverage In the Community: Develop strategic relationships to acquire pipeline products and capital for R&D

How we listen

SOURCE: Self-reported by organization

Seeking feedback from people served makes programs more responsive and effective. Here’s how this organization is listening.

done We shared information about our current feedback practices.
  • How is your organization using feedback from the people you serve?

  • Which of the following feedback practices does your organization routinely carry out?

  • What challenges does the organization face when collecting feedback?


Fiscal year: Jan 01 - Dec 31
Financial documents
2021 Medicines360 and Subsidiaries
done  Yes, financials were audited by an independent accountant. info

Revenue vs. expenses:  breakdown

SOURCE: IRS Form 990 info
Note: When component data are not available, the graph displays the total Revenue and/or Expense values.

Liquidity in 2021 info

SOURCE: IRS Form 990


Average of 8.56 over 10 years

Months of cash in 2021 info

SOURCE: IRS Form 990


Average of 14.2 over 10 years

Fringe rate in 2021 info

SOURCE: IRS Form 990


Average of 15% over 10 years

Funding sources info

Source: IRS Form 990

Assets & liabilities info

Source: IRS Form 990

Financial data

Source: IRS Form 990 info


Revenue & expenses

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990

Fiscal year ending: cloud_download Download Data


Balance sheet

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990

The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities must also be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.

Fiscal year ending: cloud_download Download Data


Financial trends analysis Glossary & formula definitions

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990

This snapshot of MEDICINES360’s financial trends applies Nonprofit Finance Fund® analysis to data hosted by GuideStar. While it highlights the data that matter most, remember that context is key – numbers only tell part of any story.

Created in partnership with

Business model indicators

Profitability info 2017 2018 2019 2020 2021
Unrestricted surplus (deficit) before depreciation $9,067,234 -$8,543,831 $27,912,004 -$5,230,488 -$6,155,270
As % of expenses 54.5% -40.5% 118.4% -22.8% -27.6%
Unrestricted surplus (deficit) after depreciation $8,668,097 -$8,788,818 $27,670,910 -$5,577,826 -$6,442,323
As % of expenses 50.9% -41.2% 116.2% -23.9% -28.5%
Revenue composition info
Total revenue (unrestricted & restricted) $23,326,051 $16,684,261 $17,400,453 $12,024,199 $24,675,342
Total revenue, % change over prior year 204.0% -28.5% 4.3% -30.9% 105.2%
Program services revenue 44.1% 52.7% 0.0% 0.0% 0.0%
Membership dues 0.0% 0.0% 0.0% 0.0% 0.0%
Investment income 9.2% 13.2% 12.8% 13.7% 4.3%
Government grants 0.0% 0.0% 0.0% 0.0% 0.0%
All other grants and contributions 31.4% 3.6% 45.9% 4.0% 0.1%
Other revenue 15.3% 30.5% 41.3% 82.3% 95.5%
Expense composition info
Total expenses before depreciation $16,635,102 $21,111,005 $23,572,193 $22,990,219 $22,301,887
Total expenses, % change over prior year 2.6% 26.9% 11.7% -2.5% -3.0%
Personnel 41.3% 37.0% 37.7% 43.5% 47.2%
Professional fees 36.0% 39.2% 36.0% 36.3% 34.7%
Occupancy 2.7% 2.3% 2.0% 2.3% 2.4%
Interest 0.0% 0.0% 0.0% 0.0% 0.0%
Pass-through 0.3% 0.1% 0.1% 0.0% 0.0%
All other expenses 19.7% 21.4% 24.2% 17.8% 15.7%
Full cost components (estimated) info 2017 2018 2019 2020 2021
Total expenses (after depreciation) $17,034,239 $21,355,992 $23,813,287 $23,337,557 $22,588,940
One month of savings $1,386,259 $1,759,250 $1,964,349 $1,915,852 $1,858,491
Debt principal payment $0 $0 $0 $0 $0
Fixed asset additions $0 $0 $590,484 $0 $327,162
Total full costs (estimated) $18,420,498 $23,115,242 $26,368,120 $25,253,409 $24,774,593

Capital structure indicators

Liquidity info 2017 2018 2019 2020 2021
Months of cash 4.2 2.4 1.4 0.9 1.9
Months of cash and investments 65.1 46.2 43.3 40.9 38.6
Months of estimated liquid unrestricted net assets 47.9 32.9 43.4 41.7 39.5
Balance sheet composition info 2017 2018 2019 2020 2021
Cash $5,852,048 $4,144,895 $2,804,283 $1,710,899 $3,494,867
Investments $84,338,539 $77,090,983 $82,295,121 $76,665,039 $68,172,800
Receivables $6,181,250 $3,666,563 $2,391,655 $3,257,831 $3,289,739
Gross land, buildings, equipment (LBE) $2,256,648 $2,243,424 $2,840,855 $2,836,767 $2,281,555
Accumulated depreciation (as a % of LBE) 61.0% 73.0% 66.4% 78.3% 71.3%
Liabilities (as a % of assets) 30.4% 32.3% 3.9% 4.5% 5.1%
Unrestricted net assets $67,250,867 $58,462,049 $86,132,959 $80,555,133 $74,112,810
Temporarily restricted net assets $1,314,481 $500,940 N/A N/A N/A
Permanently restricted net assets $0 $0 N/A N/A N/A
Total restricted net assets $1,314,481 $500,940 $0 $0 $0
Total net assets $68,565,348 $58,962,989 $86,132,959 $80,555,133 $74,112,810

Key data checks

Key data checks info 2017 2018 2019 2020 2021
Material data errors No No No No No


The people, governance practices, and partners that make the organization tick.

Letter of Determination is not available for this organization
Form 1023/1024 is not available for this organization

Principal Officer

Tina Raine-Bennett, MD, MPH

Tina Raine-Bennett, MD, MPH, FACOG is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California (KPNC) Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.

Number of employees

Source: IRS Form 990


Officers, directors, trustees, and key employees

SOURCE: IRS Form 990

Show data for fiscal year
Compensation data
Download up to 5 most recent years of officer and director compensation data for this organization


Highest paid employees

SOURCE: IRS Form 990

Show data for fiscal year
Compensation data
Download up to 5 most recent years of highest paid employee data for this organization


Board of directors
as of 04/03/2023
SOURCE: Self-reported by organization
Board of directors data
Download the most recent year of board of directors data for this organization
Board chair

Leslie Benet, PhD

Ann Barber

Karen Dawes

Mike Dorsey

Lisa David

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? No
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? No
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? No
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? No
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? No

Organizational demographics

SOURCE: Self-reported; last updated 3/30/2023

Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.


The organization's leader identifies as:

Race & ethnicity
Black/African American
Gender identity
Sexual orientation
Decline to state
Disability status
Decline to state

Race & ethnicity

No data

Gender identity


Sexual orientation

No data


No data

Equity strategies

Last updated: 03/30/2023

GuideStar partnered with Equity in the Center - an organization that works to shift mindsets, practices, and systems to increase racial equity - to create this section. Learn more

  • We review compensation data across the organization (and by staff levels) to identify disparities by race.
  • We employ non-traditional ways of gathering feedback on programs and trainings, which may include interviews, roundtables, and external reviews with/by community stakeholders.
  • We have long-term strategic plans and measurable goals for creating a culture such that one’s race identity has no influence on how they fare within the organization.


Fiscal year ending

Professional fundraisers

Fiscal year ending

SOURCE: IRS Form 990 Schedule G

Solicitation activities
Gross receipts from fundraising
Retained by organization
Paid to fundraiser